75272-39-8 Usage
Description
Nemonapride, also known by the brand name Emirace, is a potent dopamine D2 receptor antagonist antipsychotic. It is a benzamide diastereomer that exhibits superior efficacy against hallucinations and delusions while also being effective in treating negative symptoms. Nemonapride is characterized by its ability to readily pass through the blood-brain barrier and bind preferentially to dopamine 2 (D2)-like receptors over D1-like receptors. Additionally, it binds to sigma 1 (σ1) and σ2 receptors and activates the serotonin 1A receptor (5-HT1A). Nemonapride is a colorless crystalline solid and is known for its few side effects, primarily akinesia and some muscle rigidity, with extrapyramidal symptoms being rare.
Uses
Used in Pharmaceutical Industry:
Nemonapride is used as an antipsychotic for the treatment of various psychiatric disorders. It acts as a selective dopamine D2 receptor antagonist, providing potent neuroleptic effects in animals. Its preferential binding to D2-like receptors over D1-like receptors, along with its interaction with sigma and serotonin receptors, contributes to its effectiveness in managing hallucinations, delusions, and negative symptoms associated with psychiatric conditions.
Nemonapride is particularly useful in the treatment of schizophrenia and other psychotic disorders due to its ability to alleviate positive symptoms such as hallucinations and delusions, while also addressing negative symptoms like social withdrawal and emotional blunting. Its low incidence of extrapyramidal symptoms and muscle rigidity make it a preferred choice for patients who are sensitive to side effects commonly associated with other antipsychotic medications.
Originator
Yamanouchi (Japan)
Biological Activity
Highly potent dopamine D 2 -like receptor antagonist; selective over D 1 -like receptors (K i values are 0.1 and 740 nM for D 2 -like and D 1 -like receptors respectively). Also potent 5-HT 1A receptor agonist (IC 50 = 34 nM) and has affinity for sigma receptors.
Check Digit Verification of cas no
The CAS Registry Mumber 75272-39-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,5,2,7 and 2 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 75272-39:
(7*7)+(6*5)+(5*2)+(4*7)+(3*2)+(2*3)+(1*9)=138
138 % 10 = 8
So 75272-39-8 is a valid CAS Registry Number.
InChI:InChI=1/C21H26ClN3O2/c1-14-18(9-10-25(14)13-15-7-5-4-6-8-15)24-21(26)16-11-17(22)19(23-2)12-20(16)27-3/h4-8,11-12,14,18,23H,9-10,13H2,1-3H3,(H,24,26)
75272-39-8Relevant articles and documents
Concise, protecting-group-free synthesis of (+)-nemonapride via Eu(OTf)3-catalyzed aminolysis of 3,4-epoxy alcohol
Uesugi, Shun-Ichiro,Sasano, Yusuke,Matsui, Shogo,Kanoh, Naoki,Iwabuchi, Yoshiharu
, p. 22 - 24 (2017/01/06)
A concise, protecting-group-free synthesis of the antipsychotic agent (+)-nemonapride has been achieved featuring a europium(III) trifluoromethanesulfonate (Eu(OTf)3)-catalyzed C4 selective aminolysis of a 3,4-epoxy alcohol by benzylamine and a
Synthesis and neuroleptic activity of benzamides. cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy- 4-(methylamino)benzamide and related compounds
Iwanami,Takashima,Hirata,Hasegawa,Usuda
, p. 1224 - 1230 (2007/10/02)
-
